CrestPoint Capital Management’s Pfizer PFE Stock Holding History

CrestPoint Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$782K	Hold	22,766	–	–	0.43%	83
2017 Q3	$771K	Sell	22,766 -1,371	-6%	-$44.1K	0.34%	100
2017 Q2	$769K	Sell	24,137 -40,789	-63%	-$1.29M	0.36%	97
2017 Q1	$2.11M	Sell	64,926 -29,196	-31%	-$921K	1.01%	21
2016 Q4	$2.9M	Buy	94,122 +23,609	+33%	+$721K	1.45%	10
2016 Q3	$2.27M	Sell	70,513 -2,002	-3%	-$66.9K	1.16%	17
2016 Q2	$2.42M	Buy	72,515 +5,691	+9%	+$182K	1.29%	9
2016 Q1	$1.88M	Buy	66,824 +36,785	+122%	+$1.05M	1.02%	17
2015 Q4	$920K	Buy	30,039 +211	+0.7%	+$6.64K	0.52%	69
2015 Q3	$889K	Buy	29,828 +3,162	+12%	+$101K	0.51%	72
2015 Q2	$848K	Hold	26,666	–	–	0.45%	81
2015 Q1	$880K	Hold	26,666	–	–	0.46%	79
2014 Q4	$788K	Buy	26,666 +6,008	+29%	+$172K	0.43%	89
2014 Q3	$580K	Buy	20,658 +210	+1%	+$5.89K	0.35%	104
2014 Q2	$576K	Hold	20,448	–	–	0.34%	106
2014 Q1	$623K	Hold	20,448	–	–	0.39%	103
2013 Q4	$594K	Buy	+20,448	New	+$595K	0.39%	92

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CrestPoint Capital Management's PFE Position: Q4 2017 in Review

CrestPoint Capital Management held its Pfizer (PFE) position steady in Q4 2017 at 22,766 shares worth $782K. The position accounts for 0.43% of the portfolio, ranked #83.

CrestPoint Capital Management first reported a position in PFE in Q4 2013 and has held it in 17 quarters since. The position peaked at $2.9M in Q4 2016. 2,244 funds tracked by Wall St. Rank hold PFE as of Q4 2017.

CrestPoint Capital Management held 22,766 shares of Pfizer worth $782K as of Q4 2017.
CrestPoint Capital Management left its Pfizer share count unchanged in Q4 2017.
Pfizer made up 0.43% of CrestPoint Capital Management's portfolio in Q4 2017, its #83 holding.
CrestPoint Capital Management first reported a position in Pfizer in Q4 2013 and has held it in 17 quarters since.
CrestPoint Capital Management's Pfizer position peaked at $2.9M in Q4 2016.
2,244 funds tracked by Wall St. Rank held Pfizer as of Q4 2017.

Based on CrestPoint Capital Management's 13F filing for Q4 2017, filed 17 Jan 2018.